We are live on ! Find out more
AMBI

Ambit Biosciences Corp
AMBI

Delisted

AMBI was delisted on the 10th of November, 2014.

Back to rankings

46 hedge funds and large institutions have $78.8M invested in Ambit Biosciences Corp in 2014 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

56% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 9

31% more funds holding

Funds holding: 35 → 46 (+11)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $79.3M → $78.8M (-$510K)

Holders
46
Holders Change
+11
Holders Change %
+31.43%
% of All Funds
1.33%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
14
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.47M
2
CA
Commerzbank Aktiengesellschaft
Germany
+$753K
3
Macquarie Group
Macquarie Group
Australia
+$651K
4
EAM
Eventide Asset Management
Massachusetts
+$605K
5
IG
ING Group
Netherlands
+$531K

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$1.89M
2
SFM
Sphera Funds Management
Israel
-$908K
3
SM
Sabby Management
Florida
-$627K
4
HCM
Highbridge Capital Management
New York
-$268K
5
GPP
Great Point Partners
Connecticut
-$142K
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management I
California
$19M – – –
O
2
OrbiMed
New York
$13.6M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$8.38M – – –
BBA
4
Baker Bros. Advisors
New York
$6.82M – – –
GPP
5
Great Point Partners
Connecticut
$6.56M -$142K -13,339 -2%
WC
6
Wexford Capital
Florida
$5.05M +$244K +22,982 +4%
RG
7
Redmile Group
California
$3.35M -$1.89M -178,383 -33%
AG
8
Artal Group
Luxembourg
$2.28M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.94M +$1.47M +138,744 +188%
SFM
10
Sphera Funds Management
Israel
$1.35M -$908K -85,527 -37%
EAM
11
Eventide Asset Management
Massachusetts
$1.2M +$605K +57,000 +77%
Morgan Stanley
12
Morgan Stanley
New York
$1.14M +$453K +42,646 +52%
BIT
13
BlackRock Institutional Trust
California
$849K -$16.6K -1,568 -2%
Macquarie Group
14
Macquarie Group
Australia
$698K +$651K +61,300 +403%
CA
15
Commerzbank Aktiengesellschaft
Germany
$648K +$753K +71,000 New
NI
16
Numeric Investors
Massachusetts
$533K +$214K +20,181 +53%
DCM
17
Driehaus Capital Management
Illinois
$526K -$24.3K -2,292 -4%
BA
18
BlackRock Advisors
Delaware
$454K +$342K +32,215 +183%
IG
19
ING Group
Netherlands
$439K +$531K +50,000 New
BCM
20
Bridgeway Capital Management
Texas
$411K +$479K +45,100 New
FWIA
21
Fort Washington Investment Advisors
Ohio
$347K +$404K +38,054 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$320K +$85.9K +8,096 +30%
B
23
Bailard
California
$319K – – –
PAM
24
Panagora Asset Management
Massachusetts
$254K +$295K +27,829 New
U
25
UBS
Switzerland
$253K +$287K +27,016 +3,555%
1
2

AMBI Hedge Fund Activity: Q1 2014 in Review

46 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q1 2014, worth a combined $78.8M — down 0.64% from $79.3M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new AMBI positions and 4 closed out — a net gain of 11 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.47M. The largest seller was Redmile Group, cutting an estimated $1.89M.

  • 46 institutional investors held Ambit Biosciences Corp (AMBI) as of Q1 2014, up from 35 in Q4 2013.
  • Funds reported $78.8M of Ambit Biosciences Corp stock for Q1 2014, down 0.64% quarter-over-quarter.
  • 15 funds opened new Ambit Biosciences Corp positions in Q1 2014 and 4 closed out, a net change of +11 holders.
  • The largest Ambit Biosciences Corp buyer in Q1 2014 was Vanguard Group, an estimated $1.47M added.
  • The largest Ambit Biosciences Corp seller in Q1 2014 was Redmile Group, an estimated $1.89M sold.

Based on aggregated 13F filings for Q1 2014.